NasdaqGS:EWTXPharmaceuticals
A Look At Edgewise Therapeutics (EWTX) Valuation After Positive CIRRUS HCM Phase 2 Trial Update
Edgewise Therapeutics (EWTX) recently reported positive updates from its Phase 2 CIRRUS HCM trial for EDG-7500, a cardiac sarcomere modulator targeting hypertrophic cardiomyopathy, drawing fresh attention to the company’s broader pipeline and stock.
See our latest analysis for Edgewise Therapeutics.
The CIRRUS HCM update has arrived after a strong 90 day share price return of 53.55%, although the 1 year total shareholder return of a 7.20% decline and very large 3 year total shareholder return...